US 2022/0177573 A1 · TWO CHIMERIC ANTIGEN RECEPTORS SPECIFICALLY BINDING CD19 AND IGKAPPA

Abstract

The present disclosure relates to compositions comprising compounds or cells able to specifically bind immunoglobulin kappa (IgKappa) and membrane molecule CD 19 under physiological conditions. In particular, the disclosure relates to a combinatorial chimeric antigen receptor (cCAR) with antigen binding domains specific for the antigen CD19 and the immunoglobulin (Ig) Kappa light chain and their expression in immune effector cells to target cells expressing CD19 and IgKappa, and such immune cells for use in treating B-cell cancers.

Claims13

Dependent claims

A cytotoxic immune cell expressing at least two CARs in the cell membrane, the CARs comprising

i. a first CAR specific for CD19 comprising an extracellular domain, a transmembrane domain and an intracellular costimulatory domain;
and
ii. a second CAR specific for IgKappa comprising an extracellular domain, a transmembrane domain and an intracellular signaling domain.

Dependencies are inferred from the claim text.

Facts

Application

17/258,238Filed 8 Jul 2019

Priority

NO 201809639 Jul 2018

Published

9 Jun 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification25 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/421
Receptors, cell surface antigens or cell surface determinants: immunoglobulin superfamily

Two chimeric antigen receptors specifically binding cd19 and igkappa

Life of this patent

Two chimeric antigen receptors specifically binding cd19 and igkappa

Life of this patent

Abstract

Claims13